GLP-1 resistance may explain why Ozempic doesn't work effectively for a subset of patients. About 10% of the population carries certain genetic variants linked to this newly identified phenomenon. In these individuals, levels of the hormone GLP-1 (glucagon-like peptide-1), which helps regulate blood sugar, are actually higher than normal but appear to be less effective at doing their job.
GLP-1 drugs like Ozempic (semaglutide) and Wegovy mimic this gut hormone to stimulate insulin release, slow gastric emptying, reduce appetite, and improve blood sugar control. They are typically prescribed at higher doses for weight loss than for diabetes. However, variability in response has puzzled clinicians. A groundbreaking study published March 29 in Genome Medicine sheds light on this, representing a decade of work involving human experiments, mouse models, and clinical trial analysis.
The Study Behind GLP-1 Resistance Discovery
The research, led by senior authors Anna Gloyn, DPhil, professor of pediatrics and genetics, and Markus Stoffel, MD, PhD, professor of metabolic diseases at ETH Zurich, pinpoints variants in the PAM gene (peptidyl-glycine alpha-amidating monooxygenase) as a key factor. Lead authors include Mahesh Umapathysivam, MBBS, DPhil, from Adelaide University, and Elisa Araldi, PhD, from the University of Parma.
"In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment," said Anna Gloyn. "At that point, a doctor would likely change the patient's drug regimen. Knowing ahead of time who is likely to respond would help patients get on the right drugs faster -- a step toward precision medicine."
Umapathysivam added: "When I treat patients in the diabetes clinic, I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically. This is the first step in being able to use someone's genetic make-up to help us improve that decision-making process."
PAM Gene's Critical Role in Hormone Activation
PAM is unique because it's the only enzyme capable of amidation, a chemical process that increases the half-life and potency of peptides like GLP-1. "PAM is a truly fascinating enzyme," Gloyn explained. "We thought, if you have a problem with this enzyme, there's going to be multiple aspects of your biology that are not working properly."
Previous studies linked PAM variants to diabetes risk and impaired insulin release. This team investigated if they also disrupt GLP-1, produced in the gut post-meal to control blood sugar.
Human Experiments Reveal Unexpected Findings
Researchers studied adults with and without the PAM variant p.S539W, who drank a sugary solution with blood tested every five minutes over four hours (non-diabetics to avoid confounders). Contrary to expectations of lower GLP-1 levels, carriers had higher circulating GLP-1 but no enhanced blood sugar reduction.
"Despite people with the PAM variant having higher circulating levels of GLP-1, we saw no evidence of higher biological activity," Gloyn said. "They were not reducing their blood sugar levels more quickly. More GLP-1 was needed to have the same biological effect, meaning they were resistant to GLP-1."
Mouse Models Confirm GLP-1 Resistance
To verify, collaborators in Zurich used PAM-deficient mice, which mirrored human results: elevated GLP-1 without improved glucose control. These mice had faster gastric emptying unresponsive to GLP-1 drugs, plus reduced pancreatic and gut responsiveness—despite normal receptor numbers.
Further Copenhagen experiments ruled out issues with GLP-1 binding or signaling, pointing to downstream pathway defects. "We couldn't understand this, which is why we looked as many different ways as we could," Gloyn noted.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Clinical Trial Data: Poorer Response to GLP-1 Drugs
Analyzing three trials (1,119 diabetes participants), PAM variant carriers (p.S539W and p.D563G) showed inferior responses. After six months, 25% of non-carriers reached HbA1c targets vs. 11.5% (p.S539W) and 18.5% (p.D563G). Strikingly, responses to sulfonylureas, metformin, and DPP-4 inhibitors were unaffected.
"What was really striking was that we saw no effect from whether you have a variant on your response to other types of diabetes medications," Gloyn said. "We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology."
Two pharma-funded trials with longer-acting GLP-1s showed no differences, suggesting these may bypass resistance.
Implications for Patients Using Ozempic and Wegovy
For the 10% with PAM variants, GLP-1 drugs like Ozempic may require dose adjustments, switches to longer-acting options, or alternatives. It remains unclear if this impacts weight loss, as limited trial data showed no clear differences—though more research is needed.
Patients experiencing suboptimal blood sugar control or weight loss on GLP-1 therapy should discuss genetic testing with their doctor. Precision medicine could identify non-responders early, avoiding trial-and-error. Tools like Shotlee for tracking symptoms and medication responses can help monitor progress between visits.
Common GLP-1 side effects (nausea, vomiting, diarrhea) persist regardless of genetics, but poor responders may face prolonged frustration. Always consult providers before changes.
Comparing GLP-1 Drugs to Alternatives
Unlike broad-acting meds like metformin, GLP-1 agonists target incretin pathways specifically—explaining PAM specificity. For resistant patients, insulin sensitizers or combinations may work, akin to insulin resistance management.
Unresolved Questions in GLP-1 Resistance
The mechanism remains elusive: "That is the million-dollar question," Gloyn said. "We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about. No matter what we've done, we've not been able to nail precisely why they are resistant."
Like insulin resistance, it may involve multifactorial biology. Future genetic data from GLP-1 trials could clarify weight loss predictors. Contributors from Oxford, Dundee, Copenhagen, and others advanced this work, funded by Wellcome, MRC, NIH, and more.
Key Takeaways: What This Means for Patients
- 10% prevalence: PAM variants (e.g., p.S539W, p.D563G) cause GLP-1 resistance with higher but ineffective hormone levels.
- Specific to GLP-1 drugs: No impact on metformin, sulfonylureas, or DPP-4i.
- Clinical impact: Reduced HbA1c target achievement (11.5-18.5% vs. 25%).
- Precision potential: Genetic screening for tailored therapy.
- Weight loss unclear: Limited data; longer-acting GLP-1s promising.
Conclusion: Toward Personalized Metabolic Therapy
This study advances understanding of why Ozempic doesn't work for everyone, highlighting GLP-1 resistance via PAM variants. While mechanisms puzzle scientists, it opens doors to genetic-guided care, optimizing outcomes in diabetes and obesity management. Discuss with your endocrinologist for personalized strategies.
